

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2003 WYOMING

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	65,974	199	4,704	12,484	48,587	0	579,593	1,565	48,415	90,803	438,810	0
Age												
5 and younger	21,408	0	246	1	21,161	0	192,559	0	2,500	10	190,049	0
6-14	19,772	0	735	1	19,036	0	185,424	0	8,079	2	177,343	0
15-20	9,499	4	555	609	8,331	0	80,734	29	5,894	3,692	71,119	0
21-44	12,898	58	1,649	11,132	59	0	98,732	497	16,858	81,078	299	0
45-64	2,292	42	1,515	735	0	0	21,449	361	15,077	6,011	0	0
65-74	34	30	4	0	0	0	270	263	7	0	0	0
75-84	27	27	0	0	0	0	165	165	0	0	0	0
85 and older	40	38	0	2	0	0	254	250	0	4	0	0
Unknown	4	0	0	4	0	6	0	0	0	6	0	0
Gender												
Female	36,774	170	2,534	10,156	23,914	0	317,232	1,365	26,345	74,126	215,396	0
Male	29,142	29	2,170	2,328	24,615	0	262,054	200	22,070	16,677	223,107	0
Unknown	58	0	0	0	58	0	307	0	0	0	307	0
Race												
White	51,641	178	3,705	10,019	37,739	0	450,755	1,408	38,369	71,635	339,343	0
African American	1,202	0	105	153	944	0	11,222	0	1,001	1,135	9,086	0
Other/unknown	13,131	21	894	2,312	9,904	0	117,616	157	9,045	18,033	90,381	0
Use of Nursing Facilities^c												
Entire year	91	27	64	0	0	0	815	250	565	0	0	0
Part year	91	10	79	2	0	0	833	83	726	24	0	0
None	65,792	162	4,561	12,482	48,587	0	577,945	1,232	47,124	90,779	438,810	0
Maintenance Assistance Status												
Cash	17,020	23	3,362	6,064	7,571	0	149,951	203	34,053	44,892	70,803	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	35,554	104	2	3,383	32,065	0	312,147	898	18	20,041	291,190	0
Other/unknown	13,400	72	1,340	3,037	8,951	0	117,495	464	14,344	25,870	76,817	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	65,974	199	4,704	12,484	48,587	0	579,593	1,565	48,415	90,803	438,810	0
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c	Rx \$ as a Percentage of All Medicaid FFS \$ ^d	Number of Beneficiaries
All	64.2 %	6.2	\$350	\$57	\$2,904	12.1 %	65,974
Age							
5 and younger	66.3	3.7	138	38	1,872	7.4	21,408
6-14	59.6	4.3	251	58	1,760	14.2	19,772
15-20	61.8	5.6	338	60	2,698	12.5	9,499
21-44	67.9	9.3	568	61	5,143	11.0	12,898
45-64	74.0	29.6	1,971	67	10,101	19.5	2,292
65-74	64.7	41.4	2,266	55	21,000	10.8	34
75-84	59.3	27.3	1,138	42	12,581	9.0	27
85 and older	55.0	32.1	1,463	46	13,282	11.0	40
Unknown	0.0	0.0	0	0	5	0.0	4
Basis of Eligibility^e							
Aged	62.3	22.8	1,221	54	11,252	10.8	199
Disabled	78.3	26.1	2,118	81	15,921	13.3	4,704
Adults	66.6	7.3	332	46	2,882	11.5	12,484
Children	62.2	3.9	180	46	1,615	11.2	48,587
Unknown	0.0	0.0	0	0	0	0.0	0
Gender							
Female	67.1	7.0	368	53	3,026	12.2	36,774
Male	60.6	5.2	329	64	2,755	11.9	29,142
Unknown	15.5	0.6	11	17	233	4.7	58
Race							
White	66.8	6.7	380	57	2,980	12.7	51,641
African American	63.5	5.7	330	58	2,193	15.0	1,202
Other/unknown	54.1	4.3	238	55	2,669	8.9	13,131
Use of Nursing Facilities^f							
Entire year	94.5	66.6	3,822	57	40,975	9.3	91
Part year	96.7	57.6	4,165	72	47,469	8.8	91
None	64.1	6.0	340	56	2,790	12.2	65,792
Maintenance Assistance Status							
Cash	64.0	9.4	598	64	3,140	19.0	17,020
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	63.3	3.8	163	43	1,376	11.9	35,554
Other/unknown	66.8	8.5	532	63	6,659	8.0	13,400

Table ND3

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	Number of Rx. Percentage with:										Beneficiaries	Number
	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS ^c	None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS ^d		
All	0.7	\$40	12.1 %	35.8 %	52.7 %	5.6 %	4.3 %	1.3 %	0.3 %	\$331	65,974	579,593
Age												
5 and younger	0.4	15	7.4	33.7	61.9	3.4	0.9	0.0	0.0	208	21,408	192,559
6-14	0.5	27	14.2	40.4	52.3	4.1	2.9	0.3	0.0	188	19,772	185,424
15-20	0.7	40	12.5	38.2	49.8	6.9	4.4	0.7	0.0	318	9,499	80,734
21-44	1.2	74	11.0	32.1	45.7	9.8	9.0	2.9	0.5	672	12,898	98,732
45-64	3.2	211	19.5	26.0	23.1	10.4	21.6	14.6	4.4	1,079	2,292	21,449
65-74	5.2	285	10.8	35.3	5.9	5.9	32.4	11.8	8.8	2,644	34	270
75-84	4.5	186	9.0	40.7	18.5	3.7	11.1	22.2	3.7	2,059	27	165
85 and older	5.1	230	11.0	45.0	2.5	5.0	20.0	20.0	7.5	2,092	40	254
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	3	4	6
Basis of Eligibility^e												
Aged	2.9	155	10.8	37.7	23.6	9.0	15.1	11.1	3.5	1,431	199	1,565
Disabled	2.5	206	13.3	21.7	31.9	11.7	20.6	11.2	2.9	1,547	4,704	48,415
Adults	1.0	46	11.5	33.4	47.5	9.4	7.6	1.8	0.2	396	12,484	90,803
Children	0.4	20	11.2	37.8	56.1	4.0	1.9	0.2	0.0	179	48,587	438,810
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Gender												
Female	0.8	43	12.2	32.9	53.6	6.4	5.0	1.6	0.4	351	36,774	317,232
Male	0.6	37	11.9	39.4	51.6	4.6	3.5	0.9	0.1	306	29,142	262,054
Unknown	0.1	2	4.7	84.5	15.5	0.0	0.0	0.0	0.0	44	58	307
Race												
White	0.8	44	12.7	33.2	54.2	6.1	4.8	1.5	0.3	341	51,641	450,755
African American	0.6	35	15.0	36.5	53.7	4.2	4.5	1.0	0.1	235	1,202	11,222
Other/unknown	0.5	27	8.9	45.9	46.8	3.9	2.6	0.7	0.1	298	13,131	117,616
Use of Nursing Facilities^f												
Entire year	7.4	427	9.3	5.5	2.2	5.5	27.5	38.5	20.9	4,575	91	815
Part year	6.3	455	8.8	3.3	9.9	4.4	30.8	37.4	14.3	5,186	91	833
None	0.7	39	12.2	35.9	52.8	5.6	4.3	1.2	0.2	318	65,792	577,945
Maintenance Assistance Status												
Cash	1.1	68	19.0	36.0	45.1	7.4	7.8	3.1	0.6	356	17,020	149,951
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.4	19	11.9	36.7	56.9	4.4	1.9	0.1	0.0	157	35,554	312,147
Other/unknown	1.0	61	8.0	33.2	51.3	6.5	6.3	2.2	0.5	760	13,400	117,495

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
 - d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
 - e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
All	0.7	\$40	\$57	0.3	\$31	\$98	0.0	\$1	\$54	0.4	\$7	\$20
Age												
5 and younger	0.4	15	38	0.2	11	65	0.0	1	39	0.2	3	16
6-14	0.5	27	58	0.2	22	87	0.0	1	63	0.2	4	21
15-20	0.7	40	60	0.3	31	99	0.0	2	63	0.3	7	21
21-44	1.2	74	61	0.5	58	118	0.0	2	51	0.7	14	20
45-64	3.2	211	67	1.4	161	118	0.1	9	59	1.6	41	25
65-74	5.2	285	55	2.2	211	98	0.2	4	26	2.9	67	24
75-84	4.5	186	42	1.5	115	79	0.2	5	28	2.7	59	21
85 and older	5.1	230	46	1.7	160	94	0.6	11	20	2.8	59	21
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility^d												
Aged	2.9	155	54	1.1	114	101	0.2	4	25	1.6	35	22
Disabled	2.5	206	81	1.2	165	139	0.1	8	68	1.2	32	26
Adults	1.0	46	46	0.4	34	91	0.0	1	40	0.6	11	18
Children	0.4	20	46	0.2	15	75	0.0	1	49	0.2	4	18
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Gender												
Female	0.8	43	53	0.3	32	93	0.0	2	50	0.4	9	20
Male	0.6	37	64	0.3	30	105	0.0	1	62	0.3	6	21
Unknown	0.1	2	17	0.0	1	29	0.0	0	37	0.1	1	11
Race												
White	0.8	44	57	0.3	34	98	0.0	2	53	0.4	8	20
African American	0.6	35	58	0.3	26	90	0.0	1	55	0.3	8	27
Other/unknown	0.5	27	55	0.2	20	101	0.0	1	60	0.3	5	20
Use of Nursing Facilities^e												
Entire year	7.4	427	57	2.9	319	108	0.5	12	25	4.0	95	24
Part year	6.3	455	72	2.1	325	156	0.3	13	37	3.9	116	30
None	0.7	39	56	0.3	30	97	0.0	1	55	0.3	7	20
Maintenance Assistance Status												
Cash	1.1	68	64	0.5	53	115	0.0	3	61	0.6	12	22
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Poverty related	0.4	19	43	0.2	14	71	0.0	1	51	0.2	4	18
Other/unknown	1.0	61	63	0.5	48	106	0.0	2	48	0.5	10	22

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Wyoming, 1.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Therapeutic Category	Number of Rx per Benefit Month Among Users			\$ per Benefit Month Among Users			\$ per Rx			Users ^e							
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	Percentage of All Beneficiaries	Number of Benefit Months				
														Patented Brand-Name	Off-Patent Brand-Name	Generic	
Anti-infective Agents	0.2	0.1	0.0	0.1	\$10	\$7	\$0	\$3	\$40	\$59	\$65	\$21	74,177	\$3,002,933	30,044	45.5 %	306,702
Biologicals	0.2	0.2	0.0	0.0	210	189	1	20	885	846	632	1,620	516	456,913	226	0.3	2,177
Antineoplastic Agents	0.5	0.3	0.0	0.2	230	211	4	15	467	684	278	88	668	312,013	134	0.2	1,354
Endocrine/Metabolic Drugs	0.4	0.2	0.1	0.1	19	15	2	3	52	83	33	21	30,447	1,569,543	8,136	12.3	81,094
Cardiovascular Agents	0.8	0.3	0.0	0.5	30	20	1	9	37	72	30	17	22,199	811,670	2,710	4.1	27,448
Respiratory Agents	0.3	0.2	0.0	0.2	15	11	0	3	44	72	44	19	69,322	3,082,502	20,283	30.7	209,440
Gastrointestinal Agents	0.4	0.2	0.0	0.2	31	24	1	6	88	128	213	36	16,075	1,409,680	4,516	6.8	44,932
Genitourinary Agents	0.2	0.2	0.0	0.1	11	10	0	1	49	60	34	18	5,209	254,310	2,365	3.6	22,774
CNS Drugs	0.7	0.5	0.0	0.3	65	57	2	6	89	125	123	23	55,662	4,927,884	7,615	11.5	75,452
Stimulants/Anti-obesity/Anorexia	0.7	0.5	0.0	0.1	53	46	2	5	78	87	58	42	17,954	1,391,755	2,496	3.8	26,220
Miscellaneous Psychological/Neurological Agents	0.4	0.4	0.0	0.0	162	161	0	1	369	409	0	14	329	121,470	72	0.1	750
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	14	8	1	5	35	140	72	14	45,589	1,584,713	11,847	18.0	116,448
Neuromuscular Agents	0.5	0.2	0.0	0.2	41	34	1	5	82	141	50	24	25,156	2,071,461	4,866	7.4	50,468
Nutritional Products	0.2	0.0	0.0	0.2	4	0	0	3	18	44	21	16	11,355	202,324	5,585	8.5	52,605
Hematological Agents	0.5	0.1	0.1	0.3	134	123	3	9	252	900	27	29	3,180	802,521	603	0.9	5,993
Topical Products	0.2	0.1	0.0	0.1	6	4	0	2	34	56	60	17	26,117	882,637	13,412	20.3	139,122
Miscellaneous Products	0.2	0.1	0.0	0.0	17	10	4	3	108	103	284	72	1,211	130,671	708	1.1	7,599
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	4	0	0	0	30	0	0	0	3,316	101,085	2,427	3.7	25,663
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	408,482	23,116,085	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Wyoming, 1.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Top 10 Drug Groups	Users			Among Users		
	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$2,392,078	2,129	3.2 %	22,383	0.6	\$194
ANTIDEPRESSANTS	2,345,825	7,386	11.2	73,985	0.5	70
ANTICONVULSANT	1,806,776	2,510	3.8	26,285	0.6	109
ANTIASTHMATIC	1,644,285	10,776	16.3	112,800	0.2	59
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	1,391,755	3,205	4.9	34,090	0.5	78
ULCER DRUGS	933,166	4,091	6.2	41,270	0.3	82
ANALGESICS - Narcotic	890,618	13,341	20.2	132,364	0.3	27
ANTIHISTAMINES	729,600	8,210	12.4	87,400	0.2	43
MACROLIDE ANTIBIOTICS	718,578	12,929	19.6	136,753	0.1	41
PENICILLINS	701,935	20,765	31.5	219,021	0.1	25
Total	13,554,616	85,342		886,351	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	All Top 10 Drug Groups					ANTIPSYCHOTICS					ANTIDEPRESSANTS						
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month
All	215,440	\$13,554,616	2,129	3.2 %	22,383	0.6	\$107	7,386	11.2 %	73,985	0.5	\$32					
Female	127,938	7,628,966	1,206	3.3	12,482	0.5	92	5,330	14.5	52,558	0.4	30					
Disabled	39,333	3,404,337	566	22.3	6,258	0.6	133	1,332	52.6	14,699	0.5	37					
5 and younger	527	27,946	1	1.0	12	0.3	28	2	1.9	24	0.6	43					
6-14	2,449	233,618	28	9.4	325	0.6	100	43	14.5	508	0.5	28					
15-20	1,877	178,355	37	18.0	414	0.7	137	93	45.1	1,049	0.5	36					
21-44	14,794	1,276,502	240	25.2	2,651	0.6	125	570	59.8	6,363	0.5	35					
45-64	19,682	1,687,680	260	26.8	2,856	0.7	145	624	64.3	6,755	0.6	39					
65-74	4	236	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
Other Eligibles	88,605	4,224,629	640	1.9	6,224	0.4	49	3,998	11.7	37,859	0.4	28					
5 and younger	15,279	515,371	7	0.1	83	0.2	19	20	0.2	240	0.4	26					
6-14	19,731	1,062,448	109	1.2	1,189	0.6	78	518	5.6	5,540	0.5	30					
15-20	14,135	710,925	141	2.7	1,432	0.4	50	904	17.6	8,800	0.4	26					
21-44	35,311	1,674,388	345	3.7	3,142	0.3	37	2,347	25.5	21,258	0.4	27					
45-64	3,236	205,902	29	6.0	282	0.3	53	189	38.9	1,806	0.5	33					
65-74	421	29,335	3	15.8	36	0.7	172	10	52.6	113	0.7	51					
75-84	204	8,395	3	20.0	36	0.8	42	4	26.7	39	1.0	63					
85 and older	288	17,865	3	8.8	24	0.7	185	6	17.6	63	0.9	65					
Male	87,489	5,925,444	923	3.2	9,901	0.6	126	2,056	7.1	21,427	0.5	35					
Disabled	23,480	2,391,597	480	22.1	5,351	0.7	162	636	29.3	6,824	0.6	43					
5 and younger	814	63,226	3	2.1	30	0.4	61	3	2.1	36	0.2	15					
6-14	5,284	493,082	103	23.5	1,145	0.7	125	104	23.7	1,164	0.6	44					
15-20	3,802	405,605	96	27.5	1,126	0.7	143	118	33.8	1,344	0.6	53					
21-44	7,700	897,449	201	28.9	2,213	0.7	193	220	31.6	2,329	0.6	44					
45-64	5,880	532,235	77	14.1	837	0.7	160	191	35.0	1,951	0.5	36					
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
Other Eligibles	64,009	3,533,847	443	1.6	4,550	0.5	84	1,420	5.3	14,603	0.5	31					
5 and younger	19,680	712,310	14	0.1	145	0.3	18	17	0.2	179	0.3	12					
6-14	28,503	1,789,999	218	2.2	2,339	0.6	93	670	6.8	7,133	0.5	32					
15-20	9,826	684,436	143	3.8	1,470	0.5	90	435	11.4	4,562	0.4	33					
21-44	4,802	278,236	57	2.8	489	0.3	47	237	11.6	2,168	0.3	26					
45-64	1,000	52,281	7	2.4	69	0.3	39	52	17.9	466	0.5	34					
65-74	122	10,435	3	27.3	33	1.0	150	6	54.5	72	0.6	46					
75-84	32	3,490	1	8.3	5	1.0	153	1	8.3	5	1.0	71					
85 and older	44	2,660	0	0.0	0	0.0	0	2	33.3	18	0.9	64					
Unknown	13	206	0	0.0	0	0.0	0	0	0.0	0	0.0	0					

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	ANTICONVULSANT				ANTIASTHMATIC				STIMULANTS/ANTI-OBESITY/ANOREXIANTS			
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean per Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean per Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean per Rx \$ per Benefit Month
All	2,510	3.8 %	26,255	\$69	10,776	16.3 %	112,800	\$15	3,205	4.9 %	34,090	\$41
Female	1,576	4.3	16,442	67	5,828	15.8	60,223	0.3	990	2.7	10,501	0.5
Disabled	810	32.0	9,009	86	945	37.3	10,581	0.4	191	7.5	2,122	0.5
5 and younger	12	11.5	128	52	40	38.5	453	0.3	1	1.0	12	0.6
6-14	70	23.6	794	145	67	22.6	798	0.2	81	27.3	907	0.6
15-20	44	21.4	505	105	35	17.0	414	0.2	26	12.6	282	0.6
21-44	354	37.1	3,912	85	296	31.1	3,329	0.3	49	5.1	562	0.5
45-64	330	34.0	3,670	72	507	52.3	5,587	0.5	34	3.5	359	0.5
65-74	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
75-84	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
85 and older	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
Other Eligibles	766	2.2	7,433	44	4,883	14.3	49,642	0.2	799	2.3	8,379	0.5
5 and younger	39	0.4	434	30	1,486	14.7	15,767	0.2	36	0.4	426	0.4
6-14	115	1.2	1,256	56	1,262	13.7	13,435	0.2	526	5.7	5,595	0.5
15-20	108	2.1	1,006	61	735	14.3	7,261	0.2	116	2.3	1,212	0.5
21-44	456	5.0	4,255	37	1,282	13.9	12,054	0.3	112	1.2	1,059	0.4
45-64	42	8.6	417	51	94	19.3	901	0.3	9	1.9	87	0.3
65-74	3	15.8	29	51	10	52.6	102	1.6	0	0.0	0	0.0
75-84	2	13.3	24	60	4	26.7	30	0.4	0	0.0	0	0.0
85 and older	1	2.9	12	16	10	29.4	92	0.8	0	0.0	0	0.0
Male	934	3.2	9,843	72	4,946	17.0	52,559	0.2	2,215	7.6	23,589	0.5
Disabled	536	24.7	5,933	84	510	23.5	5,596	0.4	279	12.9	3,158	0.6
5 and younger	22	15.5	264	117	61	43.0	673	0.3	2	1.4	24	0.1
6-14	116	26.5	1,350	84	127	29.0	1,481	0.3	168	38.4	1,898	0.6
15-20	87	24.9	997	82	53	15.2	612	0.3	81	23.2	921	0.6
21-44	206	29.6	2,212	86	108	15.5	1,136	0.3	21	3.0	240	0.6
45-64	105	19.3	1,110	77	161	29.5	1,694	0.5	7	1.3	75	0.3
65-74	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
75-84	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
85 and older	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
Other Eligibles	398	1.5	3,910	53	4,436	16.4	46,963	0.2	1,936	7.2	20,431	0.5
5 and younger	36	0.3	363	28	2,153	19.6	22,948	0.2	118	1.1	1,357	0.4
6-14	173	1.8	1,786	49	1,681	17.2	17,970	0.2	1,515	15.5	15,937	0.5
15-20	96	2.5	930	66	445	11.7	4,641	0.3	281	7.4	2,952	0.5
21-44	73	3.6	631	56	140	6.9	1,262	0.2	21	1.0	173	0.5
45-64	18	6.2	179	33	15	5.2	121	0.3	1	0.3	12	0.1
65-74	2	18.2	21	19	1	9.1	9	0.6	0	0.0	0	0.0
75-84	0	0.0	0	0	1	8.3	12	0.1	0	0.0	0	0.0
85 and older	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0
Unknown	0	0.0	0	0	2	3.2	18	0.1	0	0.0	0	0.0

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	ULCER DRUGS					ANALGESICS - Narcotic					ANTIHISTAMINES				
	Number of Users	Users as % of All Benefes	Number of Benefit Months Among Users	Mean Rx \$ per Benefit Month	Mean Number of Rx per Benefit Month	Number of Users	Users as % of All Benefes	Number of Benefit Months Among Users	Mean Rx \$ per Benefit Month	Mean Number of Rx per Benefit Month	Number of Users	Users as % of All Benefes	Number of Benefit Months Among Users	Mean Rx \$ per Benefit Month	Mean Number of Rx per Benefit Month
All	4,091	6.2%	41,270	\$23	0.3	13,341	20.2%	132,364	\$7	0.3	8,210	12.4%	87,400	\$8	0.2
Female	2,784	7.6	28,039	23	0.3	9,893	26.9	96,870	7	0.3	4,832	13.1	50,691	8	0.2
Disabled	855	33.7	9,473	36	0.4	1,625	64.1	18,045	19	0.4	596	23.5	6,756	17	0.4
5 and younger	23	22.1	235	14	0.3	12	11.5	136	1	0.1	15	14.4	180	6	0.2
6-14	25	8.4	297	19	0.4	38	12.8	447	3	0.1	58	19.5	671	11	0.2
15-20	27	13.1	309	15	0.2	681	29.1	681	2	0.2	32	15.5	364	9	0.2
21-44	310	32.5	3,462	33	0.4	693	72.7	7,795	14	0.4	231	24.2	2,610	15	0.3
45-64	470	48.5	5,170	42	0.4	821	84.6	8,984	26	0.5	260	26.8	2,931	22	0.4
65-74	0	0.0	0	0	0.0	1	25.0	2	118	2.0	0	0.0	0	0.0	0.0
75-84	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0
85 and older	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0
Other Eligibles	1,929	5.6	18,566	16	0.2	8,268	24.1	78,825	4	0.2	4,236	12.4	43,935	7	0.2
5 and younger	290	2.9	2,638	8	0.2	344	3.4	3,784	1	0.1	1,133	11.2	12,533	4	0.1
6-14	284	3.1	3,043	11	0.2	750	8.1	8,250	2	0.1	1,163	12.6	12,647	9	0.2
15-20	347	6.7	3,436	11	0.2	1,773	34.5	17,081	2	0.2	677	13.2	6,869	8	0.2
21-44	895	9.7	8,315	20	0.2	5,099	55.4	46,698	5	0.3	1,187	12.9	11,107	7	0.2
45-64	88	18.1	875	37	0.3	276	56.8	2,752	13	0.4	67	13.8	695	13	0.3
65-74	11	57.9	114	41	0.5	9	47.4	95	32	0.6	2	10.5	24	4	0.1
75-84	4	26.7	37	39	0.7	4	26.7	48	10	1.0	1	6.7	12	1.0	0.3
85 and older	10	29.4	108	30	0.5	13	38.2	117	23	0.6	6	17.6	48	2.0	1.0
Male	1,307	4.5	13,231	22	0.3	3,448	11.8	35,494	7	0.2	3,378	11.6	36,709	8	0.2
Disabled	383	17.6	4,150	39	0.4	710	32.7	7,462	19	0.3	328	15.1	3,690	16	0.3
5 and younger	21	14.8	251	22	0.3	24	16.9	260	2	0.1	34	23.9	398	7	0.2
6-14	36	8.2	419	35	0.5	52	11.9	621	2	0.1	106	24.2	1,238	12	0.2
15-20	32	9.2	369	33	0.3	60	17.2	657	2	0.1	49	14.0	570	21	0.4
21-44	151	21.7	1,611	39	0.4	275	39.5	2,790	16	0.3	88	12.6	966	18	0.4
45-64	143	26.2	1,500	43	0.5	299	54.9	3,134	29	0.5	51	9.4	518	21	0.4
65-74	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0
75-84	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0
85 and older	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0
Other Eligibles	924	3.4	9,081	15	0.2	2,738	10.2	28,032	4	0.2	3,050	11.3	33,019	7	0.2
5 and younger	389	3.5	3,598	9	0.2	526	4.8	5,748	1	0.1	1,413	12.8	15,504	4	0.1
6-14	213	2.2	2,323	10	0.2	750	7.7	8,128	1	0.1	1,213	12.4	13,192	10	0.2
15-20	119	3.1	1,283	15	0.2	683	18.0	6,983	2	0.1	313	8.2	3,278	12	0.2
21-44	152	7.5	1,401	30	0.3	669	32.8	6,062	12	0.4	90	4.4	845	10	0.2
45-64	45	15.5	410	35	0.3	104	35.7	1,045	8	0.4	18	6.2	170	10	0.2
65-74	2	18.2	24	30	0.3	4	36.4	48	9	0.3	1	9.1	12	0.8	0.3
75-84	2	16.7	24	81	0.4	1	8.3	12	13	0.8	0	0.0	0	0.0	0.0
85 and older	2	33.3	18	46	0.5	1	16.7	6	2	0.2	2	33.3	18	0.3	1.8
Unknown	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0.0

Table ND7C

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	MACROLIDE ANTIBIOTICS				PENICILLINS					
	Number of Users	Users as % of All Beneficiaries	Number of Benefit Months Among Users	Mean of Rx per Benefit Month	Number of Users	Users as % of All Beneficiaries	Number of Benefit Months Among Users	Mean of Rx per Benefit Month	Number of Beneficiaries	Number of Benefit Months
All	12,929	19.6 %	136,753	0.1	20,765	31.5 %	219,021	0.1	65,974	579,593
Female	7,406	20.1	77,380	0.1	11,516	31.3	120,177	0.1	36,772	317,229
Disabled	661	26.1	7,601	0.1	787	31.1	9,126	0.1	2,534	26,345
5 and younger	40	38.5	444	0.2	66	63.5	755	0.2	104	1,020
6-14	89	30.0	1,060	0.1	130	43.8	1,524	0.1	297	3,255
15-20	48	23.3	553	0.1	68	33.0	804	0.1	206	2,185
21-44	241	25.3	2,777	0.1	303	31.8	3,535	0.1	953	9,932
45-64	243	25.1	2,767	0.1	220	22.7	2,508	0.1	970	9,946
65-74	0	0.0	0	0.0	0	0.0	0	0.0	4	7
75-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0
85 and older	0	0.0	0	0.0	0	0.0	0	0.0	0	0
Other Eligibles	6,745	19.7	69,779	0.1	10,729	31.3	111,051	0.1	34,238	290,884
5 and younger	2,261	22.4	24,219	0.1	4,337	43.0	46,172	0.1	10,097	90,531
6-14	1,673	18.1	17,992	0.1	2,883	31.2	31,126	0.1	9,236	86,375
15-20	1,045	20.3	10,503	0.1	1,332	25.9	13,368	0.1	5,141	41,921
21-44	1,655	18.0	15,893	0.1	2,091	22.7	19,520	0.1	9,210	67,460
45-64	102	21.0	1,079	0.1	84	17.3	841	0.1	486	4,116
65-74	4	21.1	48	0.1	2	10.5	24	0.6	19	162
75-84	3	20.0	27	0.1	0	0.0	0	0.0	15	102
85 and older	2	5.9	18	0.1	0	0.0	0	0.0	34	217
Male	5,522	18.9	59,361	0.1	9,244	31.7	98,810	0.1	29,140	262,051
Disabled	390	18.0	4,458	0.1	591	27.2	6,771	0.1	2,170	22,070
5 and younger	49	34.5	561	0.1	87	61.3	1,011	0.1	142	1,480
6-14	108	24.7	1,269	0.2	186	42.5	2,193	0.1	438	4,824
15-20	73	20.9	853	0.1	84	24.1	991	0.1	349	3,709
21-44	87	12.5	986	0.2	149	21.4	1,658	0.1	696	6,926
45-64	73	13.4	789	0.1	85	15.6	918	0.1	545	5,131
65-74	0	0.0	0	0.0	0	0.0	0	0.0	0	0
75-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0
85 and older	0	0.0	0	0.0	0	0.0	0	0.0	0	0
Other Eligibles	5,132	19.0	54,903	0.1	8,653	32.1	92,039	0.1	26,970	239,981
5 and younger	2,781	25.3	29,834	0.1	4,982	45.3	52,832	0.1	11,008	99,224
6-14	1,632	16.7	17,740	0.1	2,718	27.7	29,280	0.1	9,800	90,967
15-20	514	13.5	5,393	0.1	668	17.6	7,161	0.1	3,803	32,919
21-44	185	9.1	1,735	0.1	255	12.5	2,452	0.1	2,039	14,414
45-64	19	6.5	189	0.1	28	9.6	296	0.1	291	2,256
65-74	0	0.0	0	0.0	0	0.0	0	0.0	11	101
75-84	1	8.3	12	0.1	0	0.0	0	0.0	12	63
85 and older	0	0.0	0	0.0	2	33.3	18	0.6	6	37
Unknown	1	1.6	12	0.3	5	8.1	34	0.2	62	313

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	\$427	7.4	91	815
Age				
0-64	469	7.6	65	566
65-74	484	10.9	4	45
75-84	281	6.1	7	68
85 and older	304	6.3	15	136
Unknown	0	0.0	0	0
Gender				
Female	432	8.3	52	493
Male	419	6.2	39	322
Unknown	0	0.0	0	0
Race				
White	431	7.6	77	702
African American	0	0	0	0
Other/unknown	401	6.4	14	113
Basis of Eligibility^c				
Aged	330	7.1	27	250
Disabled	470	7.6	64	565
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2003 Medicaid enrollment. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e} NONDUAL BENEFICIARIES, WYOMING, 2003

Therapeutic Category	Number of Rx per Benefit Month Among Users			\$ per Benefit Month Among Users			\$ per Rx			Users								
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents						
												Residents	Months					
Anti-infective Agents	0.5	0.2	0.0	0.2	\$35	\$24	\$2	\$9	\$76	\$107	\$225	\$39	241	\$18,257	51	56.0	%	525
Biologicals	0.2	0.1	0.0	0.0	5	4	0	1	29	31	0	23	8	232	5	5.5		44
Antineoplastic Agents	0.9	0.6	0.0	0.3	295	251	0	44	326	439	0	132	38	12,377	4	4.4		42
Endocrine/Metabolic Drugs	1.3	0.5	0.1	0.8	48	31	2	16	36	66	17	20	622	22,308	49	53.8		461
Cardiovascular Agents	2.1	0.6	0.1	1.5	60	32	2	26	28	58	14	18	1,127	31,419	56	61.5		526
Respiratory Agents	1.3	0.6	0.0	0.6	67	45	3	19	53	76	56	32	462	24,703	37	40.7		367
Gastrointestinal Agents	1.0	0.4	0.0	0.6	57	39	0	18	56	91	168	31	501	28,028	51	56.0		489
Genitourinary Agents	0.8	0.6	0.0	0.2	58	54	0	4	68	84	14	18	251	17,137	29	31.9		296
CNS Drugs	1.7	1.0	0.0	0.6	129	112	2	16	77	108	75	25	1,027	79,104	64	70.3		614
Stimulants/Anti-obesity/Anorexia	0.1	0.0	0.0	0.1	3	0	0	3	35	0	0	35	1	35	1	1.1		12
Miscellaneous Psychological/Neurological Agents	0.7	0.7	0.0	0.0	245	245	0	0	328	328	0	0	71	23,265	9	9.9		95
Analgesics and Anesthetics	1.0	0.3	0.0	0.7	44	31	1	12	42	113	23	16	480	19,999	48	52.7		458
Neuromuscular Agents	1.3	0.5	0.1	0.7	102	73	5	24	78	158	37	33	454	35,318	40	44.0		346
Nutritional Products	0.8	0.0	0.0	0.8	23	0	0	23	27	0	12	28	247	6,754	32	35.2		296
Hematological Agents	1.3	0.1	0.7	0.5	96	80	11	5	72	542	16	11	299	21,433	27	29.7		223
Topical Products	0.4	0.2	0.0	0.2	12	8	1	4	30	49	29	17	183	5,529	43	47.3		448
Miscellaneous Products	0.4	0.2	0.0	0.2	7	3	0	4	18	15	0	21	38	677	10	11.0		103
Unknown Therapeutic Category	0.9	0.0	0.0	0.0	82	0	0	0	95	0	0	0	13	1,236	2	2.2		15
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	6,063	347,811	n.a.	n.a.		n.a.

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentid=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Wyoming, 1.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Top 10 Drug Groups in Nursing Facilities	Users				Among Users			
	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month	
ANTIPSYCHOTICS	\$40,950	36	39.6 %	378	0.9	\$127	\$108	
ANTIDEPRESSANTS	33,800	61	67.0	559	0.9	64	60	
ULCER DRUGS	22,707	53	58.2	514	0.7	65	44	
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	23,265	9	9.9	95	0.7	328	245	
ANTICONVULSANT	17,311	32	35.2	282	1.0	60	61	
MUSCULOSKELETAL THERAPY AGENTS	16,504	15	16.5	143	0.9	127	115	
ANTIASTHMATIC	16,016	41	45.1	437	0.7	53	37	
HEMATOPOIETIC AGENTS	15,921	8	8.8	79	0.8	245	202	
ANTINEOPLASTICS	12,377	4	4.4	42	0.9	326	295	
ANALGESICS - Narcotic	12,472	44	48.4	413	0.8	39	30	
Total	211,323	303		2,942	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANTIDEPRESSANTS			
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	2,413	\$211,323	36	39.6 %	378	0.9	\$108	61	67.0 %	559	0.9	\$61
Female	1,600	125,872	24	46.2	254	0.8	90	34	65.4	362	0.9	56
Disabled	1,037	93,279	19	59.4	200	0.8	85	24	75.0	251	0.9	50
64 or younger	1,037	93,279	19	59.4	200	0.8	85	24	75.0	251	0.9	50
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	563	32,593	5	25.0	54	0.8	109	10	50.0	111	1.0	70
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	158	7,599	0	0.0	0	0.0	0	2	100.0	24	1.1	88
75-84	174	9,323	3	50.0	36	0.8	42	3	50.0	36	1.0	62
85 and older	231	15,671	2	16.7	18	0.8	244	5	41.7	51	0.9	66
Male	813	85,451	12	30.8	124	1.0	146	27	69.2	197	1.0	68
Disabled	715	72,874	9	28.1	98	0.9	153	23	71.9	162	1.0	64
64 or younger	715	72,874	9	28.1	98	0.9	153	23	71.9	162	1.0	64
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	98	12,577	3	42.9	26	1.0	118	4	57.1	35	1.0	88
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	45	4,387	2	100.0	21	1.0	110	1	50.0	12	1.1	132
75-84	15	1,808	1	100.0	5	1.0	153	1	100.0	5	1.0	71
85 and older	38	6,382	0	0.0	0	0.0	0	2	66.7	18	0.9	64
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispans.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	ULCER DRUGS				MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL				ANTICONVULSANT						
	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Rx \$	Number of Months Among Users	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Rx \$	Number of Months Among Users	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Rx \$	Number of Months Among Users	
All	53	58.2 %	\$44	514	0.7	9	9.9 %	95	0.7	\$245	32	35.2 %	282	1.0	\$61
Female	29	55.8	48	299	0.7	7	13.5	78	0.7	233	21	40.4	197	1.0	68
Disabled	19	59.4	53	185	0.7	4	12.5	48	0.6	307	19	59.4	173	1.0	69
64 or younger	19	59.4	53	185	0.7	4	12.5	48	0.6	307	19	59.4	173	1.0	69
65-74	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	10	50.0	40	114	0.7	3	15.0	30	0.9	116	2	10.0	24	1.5	60
64 or younger	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	2	100.0	40	24	0.8	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	2	33.3	50	24	1.0	1	16.7	12	1.2	155	2	33.3	24	1.5	60
85 and older	6	50.0	37	66	0.6	2	16.7	18	0.7	89	0	0.0	0	0.0	0
Male	24	61.5	39	215	0.7	2	5.1	17	0.9	299	11	28.2	85	1.0	47
Disabled	22	68.8	38	197	0.7	0	0.0	0	0.0	0	10	31.3	76	1.0	50
64 or younger	22	68.8	38	197	0.7	0	0.0	0	0.0	0	10	31.3	76	1.0	50
65-74	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	2	28.6	46	18	0.5	2	28.6	17	0.9	299	1	14.3	9	0.7	23
64 or younger	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0	0.0	0	0.0	0	0.0	0	1	50.0	9	0.7	23
75-84	0	0.0	0	0	0.0	1	100.0	5	1.0	138	0	0.0	0	0.0	0
85 and older	2	66.7	46	18	0.5	1	33.3	12	0.9	366	0	0.0	0	0.0	0
Unknown	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0ffed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10B

Nondual Beneficiaries

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	MUSCULOSKELETAL THERAPY AGENTS					ANTIASTHMATIC					HEMATOPOIETIC AGENTS						
	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Number of Rx	Mean Rx \$	Number of Benefit Months Among Users	Users as % of All-Year Nursing Facility Residents	Mean Number of Rx	Mean Rx \$	Number of Benefit Months Among Users	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Number of Rx	Mean Rx \$	Number of Benefit Months Among Users	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Number of Rx
All	15	16.5 %	0.9	\$115	143	41	45.1 %	0.7	\$37	437	8	8.8 %	\$202	79	0.8		
Female	9	17.3	0.8	34	90	29	55.8	0.8	40	327	4	7.7	7	36	0.4		
Disabled	8	25.0	0.8	31	78	16	50.0	0.4	31	183	3	9.4	3	27	0.3		
64 or younger	8	25.0	0.8	31	78	16	50.0	0.4	31	183	3	9.4	3	27	0.3		
65-74	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
75-84	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
85 and older	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
Other Eligibles	1	5.0	0.9	54	12	13	65.0	1.3	50	144	1	5.0	21	9	0.7		
64 or younger	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
65-74	0	0.0	0.0	0	0	4	200.0	2.3	94	48	0	0.0	0	0	0.0		
75-84	1	16.7	0.9	54	12	2	33.3	0.2	4	24	0	0.0	0	0	0.0		
85 and older	0	0.0	0.0	0	0	7	58.3	1.0	36	72	1	8.3	21	9	0.7		
Male	6	15.4	1.1	254	53	12	30.8	0.4	28	110	4	10.3	364	43	1.2		
Disabled	6	18.8	1.1	254	53	11	34.4	0.4	28	101	4	12.5	364	43	1.2		
64 or younger	6	18.8	1.1	254	53	11	34.4	0.4	28	101	4	12.5	364	43	1.2		
65-74	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
75-84	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
85 and older	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
Other Eligibles	0	0.0	0.0	0	0	1	14.3	0.6	32	9	0	0.0	0	0	0.0		
64 or younger	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
65-74	0	0.0	0.0	0	0	1	50.0	0.6	32	9	0	0.0	0	0	0.0		
75-84	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
85 and older	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		
Unknown	0	0.0	0.0	0	0	0	0.0	0.0	0	0	0	0.0	0	0	0.0		

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	ANTINEOPLASTICS				ANALGESICS - Narcotic				Mean Rx \$	Mean Number of Rx	Number of Benefit Months Among Users	Users as % of All-Year Nursing Facility Residents	Number of Users	Users as % of All-Year Nursing Facility Residents	Mean Number of Rx	All-Year Nursing Facility Residents	Benefit Months Among All-Nursing Facility Residents
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users									
All	4	4.4 %	42	0.9	\$295	44	48.4 %	413	0.8	\$30	91	815					
Female	3	5.8	36	0.7	292	28	53.8	275	0.9	37	52	493					
Disabled	2	6.3	24	0.9	429	18	56.3	178	1.0	49	32	300					
64 or younger	2	6.3	24	0.9	429	18	56.3	178	1.0	49	32	300					
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
Other Eligibles	1	5.0	12	0.2	18	10	50.0	97	0.7	13	20	193					
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
65-74	0	0.0	0	0.0	0	1	50.0	12	0.1	1	2	24					
75-84	1	16.7	12	0.2	18	2	33.3	24	0.8	6	6	63					
85 and older	0	0.0	0	0.0	0	7	58.3	61	0.7	18	12	106					
Male	1	2.6	6	2.3	309	16	41.0	138	0.6	18	39	322					
Disabled	1	3.1	6	2.3	309	15	46.9	132	0.6	18	32	265					
64 or younger	1	3.1	6	2.3	309	15	46.9	132	0.6	18	32	265					
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					
Other Eligibles	0	0.0	0	0.0	0	1	14.3	6	0.2	2	7	57					
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1					
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	21					
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	5					
85 and older	0	0.0	0	0.0	0	1	33.3	6	0.2	2	3	30					
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0					

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 91 beneficiaries who were in nursing facilities for part of their enrollment and their 833 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 WYOMING, 2003

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx		Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx as a Percentage of All Nondual Rx \$		Total Number of Beneficiaries
				Excluded Rx	Beneficiary			Excluded Rx	All Nondual Rx \$	
All	18,884	28.6%	0.8	52,658	\$22	\$1,460,043	\$28	6.3%	65,974	
Age										
5 and younger	7,304	34.1	0.7	14,831	15	312,419	21	10.6	21,408	
6-14	4,909	24.8	0.6	10,972	22	427,390	39	8.6	19,772	
15-20	2,203	23.2	0.5	5,195	15	139,011	27	4.3	9,499	
21-44	3,503	27.2	1.1	13,846	32	406,412	29	5.6	12,898	
45-64	929	40.5	3.2	7,346	72	164,849	22	3.6	2,292	
65-74	16	47.1	8.9	304	228	7,765	26	10.1	34	
75-84	8	29.6	2.0	54	23	621	12	2.0	27	
85 and older	12	30.0	2.8	110	39	1,576	14	2.7	40	
Unknown	0	0.0	0.0	0	0	0	0	0.0	4	
Basis of Eligibility^c										
Aged	61	30.7	2.8	565	60	11,909	21	4.9	199	
Disabled	2,063	43.9	3.7	17,403	173	812,602	47	8.2	4,704	
Adults	3,122	25.0	0.7	8,585	12	148,947	17	3.6	12,484	
Children	13,638	28.1	0.5	26,105	10	486,585	19	5.6	48,587	
Unknown	0	0.0	0.0	0	0	0	0	0.0	0	
Gender										
Female	11,014	30.0	0.9	32,299	22	813,324	25	6.0	36,774	
Male	7,864	27.0	0.7	20,350	22	646,587	32	6.7	29,142	
Unknown	6	10.3	0.2	9	2	132	15	20.8	58	
Race										
White	15,182	29.4	0.8	43,069	23	1,168,222	27	6.0	51,641	
African American	330	27.5	0.7	839	40	47,850	57	12.1	1,202	
Other/unknown	3,372	25.7	0.7	8,750	19	243,971	28	7.8	13,131	
Use of Nursing Facilities^d										
Entire year	49	53.8	5.5	505	150	13,649	27	3.9	91	
Part year	68	74.7	8.8	797	355	32,299	41	8.5	91	
None	18,767	28.5	0.8	51,356	21	1,414,095	28	6.3	65,792	
Maintenance Assistance Status										
Cash	5,118	30.1	1.1	18,469	27	455,555	25	4.5	17,020	
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0	
Poverty related	9,637	27.1	0.5	17,871	9	321,852	18	5.5	35,554	
Other/unknown	4,129	30.8	1.2	16,318	51	682,636	42	9.6	13,400	

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
 - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 WYOMING, 2003

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$3	\$28	\$0	\$0	579,593
Age						
5 and younger	0.1	2	21	0	0	192,559
6-14	0.1	2	39	0	0	185,424
15-20	0.1	2	27	0	0	80,734
21-44	0.1	4	29	0	1	98,732
45-64	0.3	8	22	0	2	21,449
65-74	1.1	29	26	0	5	270
75-84	0.3	4	12	0	1	165
85 and older	0.4	6	14	0	1	254
Unknown	0.0	0	0	0	0	6
Basis of Eligibility^c						
Aged	0.4	8	21	0	1	1,565
Disabled	0.4	17	47	0	2	48,415
Adults	0.1	2	17	0	0	90,803
Children	0.1	1	19	0	0	438,810
Unknown	0.0	0	0	0	0	0
Gender						
Female	0.1	3	25	0	0	317,232
Male	0.1	2	32	0	0	262,054
Unknown	0.0	0	15	0	0	307
Race						
White	0.1	3	27	0	0	450,755
African American	0.1	4	57	0	0	11,222
Other/unknown	0.1	2	28	0	0	117,616
Use of Nursing Facilities^d						
Entire year	0.6	17	27	0	2	815
Part year	1.0	39	41	0	4	833
None	0.1	2	28	0	0	577,945
Maintenance Assistance Status						
Cash	0.1	3	25	0	1	149,951
Medically needy	0.0	0	0	0	0	0
Poverty related	0.1	1	18	0	0	312,147
Other/unknown	0.1	6	42	0	1	117,495

Table ND12

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
WYOMING, 2003

Drug Category	Number of Users	Rx \$ per User	Rx \$ as a Percentage of All Part D		Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
			Total Rx \$	Excluded Rx \$			
All	23,209	\$63	\$1,460,043	100.0 %	52,658	\$28	100.0 %
Anorexia or weight loss/gain	1	36	36	0.0	1	36	0.0
Fertility drugs	1	11	11	0.0	1	11	0.0
Drugs for cosmetic purposes	24	13	306	0.0	30	10	0.1
Cough and cold medications	12,886	34	440,613	30.2	22,047	20	41.9
Vitamins and minerals	1,760	54	94,357	6.5	4,447	21	8.4
Non-prescription drugs	6,238	110	686,064	47.0	16,571	41	31.5
Barbiturates	63	58	3,666	0.3	452	8	0.9
Benzodiazepines	1,812	90	162,911	11.2	7,957	20	15.1
Other Part D Excl Rx Drugs	424	170	72,079	4.9	1,152	63	2.2

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2003. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, WYOMING, 2003

Beneficiary Characteristics	Number of Beneficiaries					Number of Benefit Months				
	All	Aged	Disabled	Adults	Unknown	All	Aged	Disabled	Adults	Unknown
All	65,974	199	4,704	12,484	0	579,124	1,512	48,323	90,488	0
Age										
5 and younger	21,408	0	246	1	0	192,559	0	2,500	10	0
6-14	19,772	0	735	1	0	185,424	0	8,079	2	0
15-20	9,499	4	555	609	0	80,721	28	5,894	3,689	0
21-44	12,898	58	1,649	11,132	0	98,462	464	16,855	80,844	0
45-64	2,292	42	1,515	735	0	21,263	342	14,988	5,933	0
65-74	34	30	4	0	0	270	263	7	0	0
75-84	27	27	0	0	0	165	165	0	0	0
85 and older	40	38	0	2	0	254	250	0	4	0
Unknown	4	0	0	4	6	0	0	0	6	0
Gender										
Female	36,774	170	2,534	10,156	0	316,763	1,312	26,253	73,811	0
Male	29,142	29	2,170	2,328	0	262,054	200	22,070	16,677	0
Unknown	58	0	0	0	58	307	0	0	0	307
Race										
White	51,641	178	3,705	10,019	0	450,380	1,355	38,298	71,393	0
African American	1,202	0	105	153	0	11,218	0	1,001	1,131	0
Other/unknown	13,131	21	894	2,312	0	117,526	157	9,024	17,964	0
Use of Nursing Facilities^c										
Entire year	91	27	64	0	0	804	250	554	0	0
Part year	91	10	79	2	0	833	83	726	24	0
None	65,792	162	4,561	12,482	0	577,487	1,179	47,043	90,464	0
Maintenance Assistance Status										
Cash	17,020	23	3,362	6,064	0	149,762	203	33,986	44,770	0
Medically needy	0	0	0	0	0	0	0	0	0	0
Poverty related	35,554	104	2	3,383	0	311,985	845	18	19,932	0
Other/unknown	13,400	72	1,340	3,037	0	117,377	464	14,319	25,786	0
Managed Care (MC) Status										
Fee-for-service (FFS) all year	65,974	199	4,704	12,484	0	579,124	1,512	48,323	90,488	0
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
 - b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
 - c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, WYOMING, 2003

	Beneficiaries and			Excluded from Cell K of Table 1	
	Benefit Months in Cell J of Table 1 Number of Beneficiaries	Number of Benefit Months	Included in Cell K of Table 1 Number of Beneficiaries	Number of Beneficiaries	Number of Benefit Months
All	65,974	579,124	65,974	0	-469
Fee-for-service (FFS) all year	65,974	579,124	65,974	0	-469
FFS part year, with Rx claims	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0

Source: Data for this table are from the MAX 2003 file for Wyoming, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.